Leading Proxy Advisory Firm ISS Recommends Phillips 66 Shareholders Vote for All Four of Elliott's Director Nominees
ISS Validates Elliott's Case for Change and Recommends Nominees Brian Coffman, Sigmund Cornelius, Michael Heim and Stacy Nieuwoudt
Notes Phillips 66's "Disappointing" Operating Performance, "Selective Disclosure, Unverifiable Claims About Various Operational Successes, and Ambiguous and Vague Responses to Otherwise Basic Questions"
Cites the Board's "Failure" to Ensure Strong Governance and Board Oversight as Evidence of the Company's "Disconnect from Shareholders"
All Three Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Have Now Endorsed Elliott's Case for Change at Phillips 66
WEST PALM BEACH, Fla., May 12, 2025 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott"), which manages funds that together make it a top-five shareholder in Phillips 66 (NYSE: PSX) (the "Company" or "Phillips"), today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that shareholders support all four of Elliott's nominees: Brian Coffman, Sigmund Cornelius, Michael Heim and Stacy Nieuwoudt.
ISS's report follows reports issued by Glass, Lewis & Co., LLC ("Glass Lewis") and Egan-Jones Ratings Company ("Egan-Jones"), both of which also advised shareholders to support meaningful boardroom change at Phillips 66. Shareholders will have the opportunity to vote for the election of Elliott's nominees to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting") on May 21, 2025.
Elliott stated:
"By recommending that Phillips 66 shareholders vote for all four Elliott nominees, ISS has now fully validated Elliott's case for change – making clear that the status quo at the Company has failed to serve shareholders. Notably, ISS cited Phillips 66's disappointing operating performance, poor corporate governance and 'track record of providing selective and ambiguous disclosure' as reasons to support Elliott's 'strong slate.' With all three proxy advisory firms having endorsed Elliott's case, it is clearer than ever that urgent and meaningful change is needed in the Phillips 66 boardroom. In our view, electing all four of Elliott's independent, highly qualified nominees represents the surest step toward restoring accountability and driving improved long-term performance at Phillips 66."
In its report, ISS supported Elliott's case for change at Phillips 66, stating:
"In summary, the dissident has assembled a strong slate, which has the experience and independence that PSX requires."
"Operating performance has been disappointing, particularly when considered alongside management's messaging. The big picture is that PSX has not been able to sustain improvements or contend with market volatility effectively. This is clearly reflected in vacillating performance over the past three years, which culminated in deterioration relative to peers in 2024. It has also become increasingly evident that there is a disconnect between communication and results."
"The board's [decision to combine the Chair and CEO roles] evidences a disconnect from shareholders, and undermines the argument about its commitment to ensuring strong corporate governance and board oversight."
ISS criticized the Board's performance and strategy, noting:
"…the data does not support the board's argument that the integrated strategy results in superior returns over the long-term…"
"PSX has established a track record of providing selective and ambiguous disclosure that obfuscates results, makes it difficult to assess decisions, and creates impediments to evaluating performance. All in, it is difficult to view turnaround efforts since the CEO transition as successful."
"…despite claims that PSX has made significant improvements since the CEO transition, the refining segment has struggled more than peers to contend with shifting market conditions. These and other concerns have been reflected in TSR. Returns have been positive, but PSX began underperforming refining peers in mid-2021, and has not been able to close the gap."
"PSX has also struggled over all historical measurement periods relative to midstream peers. Communication with investors has provided minimal assurance about these concerns. Instead, PSX has presented shareholders with selective disclosure, unverifiable claims about various operational successes, and ambiguous and vague responses to otherwise basic questions. In other words, shareholders cannot adequately assess the strategy or performance."
ISS detailed the Board's poor corporate governance and misguided refreshment efforts, writing:
"…there are serious concerns with the manner in which the board communicates important financial information to shareholders. This is part of a broader pattern that is also reflected in evasive maneuvers and defensive statements made by the board during this proxy contest."
"When the dissident went public in November 2023, the majority of the most relevant refining and midstream experience on the board was concentrated in the hands of the legacy directors. The settlement should have been the first step in addressing this defect. On Feb. 13, 2024, the board appointed Robert Pease. He was expected to be the first of two additions made in cooperation with the dissident. Instead, he was the only one, and his alignment with the board has become an important point in this contest."
"Although the board has been reshaped since the pandemic, important industry perspectives have been overlooked, and there is strong evidence that the board is not willing to exercise independent oversight of management. The addition of Pease could have been the first step toward addressing these deficiencies. However, his decision to support the recombination of the chair and CEO positions raises questions about whether he is an independent voice on the board. Lowe is a member of the legacy cohort, which has failed to support appropriate corporate governance and has overseen sustained underperformance."
ISS also outlined the benefits of adding Elliott's nominees to the Board, stating:
"Coffman and Heim offer focused experience in refining and midstream operations, which makes them logical additions. Cornelius has a well-rounded perspective of the industry, which includes senior leadership positions and extensive board service. Thus, he would not only fortify the board's independent industry experience, but he could provide a valuable perspective if PSX considers a separation of the midstream segment."
"…Nieuwoudt offers an important perspective through her experience as an industry investor and analyst. With her background and independence, she should be able to begin repairing PSX's credibility, which has been damaged through years of suboptimal communication with investors."
Independent proxy advisory firm Glass Lewis also recently confirmed Elliott's case for change, stating:
"In our view, the more compelling case is offered by Elliott, in this case by a relatively decisive margin."
"…we believe the core argument that P66 has failed to drive compelling shareholder returns or a differentiated valuation as an extension of management's pursuit of further integration is fundamentally sound. We further consider Elliott lands much more effective ripostes on matters of cost management, synergy value and capital allocation, crimping core tenets of P66's defense."
"These issues stack on what we consider to be fairly disconcerting corporate governance considerations, including a dubious commitment to good faith engagement, a questionable and counterproductive realignment of key oversight roles and a late-stage candidate pivot which seems to call into question the board's prior candor. These issues should, in our view, be of significant concern to P66 investors."
"Narrative friction is at the fore, in our view, as the board firmly asserts that significant steps toward integration have been successful and 'will continue to drive long-term value' for investors. On review, this perspective appears disconcertingly disconnected from the boots-on-the-ground reality: P66 has regularly run afoul of market expectations, has not generated competitive value during the span of Mr. Lashier's executive service…"
Egan-Jones has also recommended support for all four of Elliott's nominees, writing that:
"…Elliott's nominees possess a strong mix of best-in-class industry expertise and experience and have the potential to unlock value for shareholders…"
"Phillips 66's current conglomerate structure appears to be suboptimal for sustained financial growth. We agree with the dissidents that a strategic shift towards refocusing on its core assets, particularly within the refining segment, is necessary to drive improved performance and value creation."
"Currently, the Company has a combined Chairman and CEO leadership structure, a classified board, and over-tenured directors. A plethora of these problematic governance practices appear to be a driving force in the Company's underperformance. We believe that addressing these structural issues would enhance accountability and exercise of the directors' fiduciary duties."
For more information, including how to vote on Elliott's GOLD proxy card, please visit Streamline66.com.
ADDITIONAL INFORMATION
Elliott Investment Management L.P., together with the other participants in Elliott's proxy solicitation (collectively, "Elliott"), has filed a definitive proxy statement and accompanying GOLD universal proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit proxies with respect to the election of Elliott's slate of highly qualified director candidates and the other proposals to be presented at the 2025 annual meeting of stockholders (the "Annual Meeting") of Phillips 66, a Delaware corporation ("Phillips" or the "Company"). Stockholders are advised to read the proxy statement and any other documents related to the solicitation of stockholders of the Company in connection with the Annual Meeting because they contain important information, including information relating to the participants in Elliott's proxy solicitation. These materials and other materials filed by Elliott with the SEC in connection with the solicitation of proxies are available at no charge on the SEC's website at http://www.sec.gov. The definitive proxy statement and other relevant documents filed by Elliott with the SEC are also available, without charge, by directing a request to Elliott's proxy solicitor, Okapi Partners LLC, at its toll-free number (877) 629-6357 or via email at info@okapipartners.com.
About Elliott
Elliott Investment Management L.P. (together with its affiliates, "Elliott") manages approximately $72.7 billion of assets as of December 31, 2024. Founded in 1977, it is one of the oldest funds under continuous management. The Elliott funds' investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm.
Media Contact:Casey Friedman Elliott Investment Management L.P. (212) 478-1780cFriedman@elliottmgmt.com
Investor Contact: Bruce Goldfarb / Pat McHughOkapi Partners LLC(877) 629-6357(212) 297-0720info@okapipartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/leading-proxy-advisory-firm-iss-recommends-phillips-66-shareholders-vote-for-all-four-of-elliotts-director-nominees-302453130.html
SOURCE Elliott Investment Management L.P.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
33 minutes ago
- Business Wire
VSTS Investors Have Opportunity to Lead Vestis Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vestis Corporation ('Vestis' or 'the Company') (NYSE: VSTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 2, 2024 and May 6, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before August 8, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Vestis misled investors about the actual extent of its ability to grow the business. The Company was not equipped to execute on planned strategic initiatives. The Company struggled to bring in new customers and retain existing customers. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Vestis, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
36 minutes ago
- Yahoo
2 Weight Loss Drug Stocks That Are Screaming Buys in June
Novo Nordisk and Eli Lilly have most of the GLP-1 drug market to themselves. Based on current pipelines, this state of affairs could continue. Both stocks are attractively priced at the moment. 10 stocks we like better than Novo Nordisk › Is there a hotter trend in healthcare than weight loss drugs? Probably not. Research from Morgan Stanley suggests that sales of weight loss drugs will soar from an estimated $15 billion last year to as much as $150 billion by 2035. That would be a tenfold increase in just over a decade. Most current medications for weight loss are GLP-1 agonists, which suppress patients' appetites by slowing digestion and making them feel full. Two companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), currently dominate this area, together accounting for an estimated 97% of the market share. Can they can stay atop this fast-growing industry? Here's what I found -- and why they could both be screaming buys right now in June 2025. Whenever an opportunity exhibits such rapid growth, it will inevitably attract competition. Indeed, numerous companies are currently developing weight loss drugs. However, it's quite a leap to assume that Novo Nordisk, with 62% of the GLP-1 market, and Eli Lilly with another 35%, will easily cede their market share to new products. First and foremost, drug development is a challenging process that undergoes rigorous regulatory testing. Many of the drugs in development today will ultimately fail to reach the market. In April, industry heavyweight Pfizer abandoned development of its oral weight loss drug danuglipron, after it may have caused a liver injury in a patient during a clinical trial. Weight loss drugs that do make it to market must then actually compete with what patients already use. That boils down to more than price: Efficacy, side effects, and prescribers' comfort levels with products all make a difference in how these treatments ultimately sell. The weight loss opportunity is currently in its early innings. The leading drugs -- Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound -- are injected, require refrigeration, and remain expensive for patients. Upcoming drugs will include more convenient oral pills; some could be cheaper to produce, and thus could be sold at lower prices. Naturally, Novo Nordisk and Eli Lilly have remained active in order to stay atop the market. Novo Nordisk could soon have an oral GLP-1 agonist for sale; it has filed an application for approval of an oral version of Wegovy. The company hopes to receive a nod by the end of this year. Additionally, its candidate CagriSema, a potential successor to Wegovy, is working through phase 3 trials. At this rate, CagriSema could arrive sometime next year. Eli Lilly is also very active. Its experimental oral weight loss drug, orforglipron, has performed well in phase 3 studies. It could be the first small-molecule drug to hit the market; small-molecule drugs are easier and cheaper to manufacture. Its next-generation injectable therapy, retatrutide, is innovative in that it targets three separate hormones related to hunger. Retatrutide is also currently in phase 3 studies, and could arrive in 2027 if all goes well. Boehringer Ingelheim's survodutide, an injected therapy that could arrive in 2027, is arguably the only potential near-term competition worth noting. There aren't any other immediate threats to Novo Nordisk and Eli Lilly's dominance. The next hopeful, MariTide from Amgen, only begins phase 3 studies in March; if approved, its estimated market arrival would be in 2028. Barring something unexpected, Novo Nordisk and Eli Lilly appear well positioned to capture much of that explosive growth in the weight loss market over the coming years. The question is, which industry giant will do better? Wall Street is currently placing its money on Eli Lilly, as evidenced by the stock's significant valuation premium. Shares trade at a price-to-earnings (P/E) ratio of 62, versus just 22 for Novo Nordisk. Novo Nordisk's CagriSema has struggled to outperform existing treatments in clinical trials, while Eli Lilly's orforglipron has performed well. However, how patients choose treatments involves several factors, so it's not a sure thing that Eli Lilly will capture all this market share from Novo Nordisk. The best solution? Own both. One way to value them is by their PEG ratios, which weigh the stocks' valuations against the companies' expected growth rates: Novo Nordisk PEG ratio: 1.5 Eli Lilly PEG ratio: 1.9 Both companies are reasonably priced for their expected long-term earnings growth, currently 14% annualized for Novo Nordisk and 32% annualized for Eli Lilly. Of course, that could play out differently, but it's all the more reason to own both stocks. One way or another, these two companies will likely split the upside in the weight loss drug market. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Weight Loss Drug Stocks That Are Screaming Buys in June was originally published by The Motley Fool
Yahoo
36 minutes ago
- Yahoo
1 Mooning Stock with Exciting Potential and 2 to Think Twice About
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. However, not all companies with momentum are long-term winners, and many investors have lost money by following short-term trends. All that said, here is one stock we think lives up to the hype and two best left ignored. One-Month Return: +7.4% Founded by brothers Walt and Roy, Disney (NYSE:DIS) is a multinational entertainment conglomerate, renowned for its theme parks, movies, television networks, and merchandise. Why Do We Think DIS Will Underperform? Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 3.7% over the last five years was below our standards for the consumer discretionary sector Capital intensity will likely increase as its free cash flow margin is anticipated to drop by 5.3 percentage points over the next year Underwhelming 5.7% return on capital reflects management's difficulties in finding profitable growth opportunities Disney is trading at $113.73 per share, or 20.6x forward P/E. Check out our free in-depth research report to learn more about why DIS doesn't pass our bar. One-Month Return: +0.3% With roots dating back to 1888 when founder Dr. Wallace Abbott began producing precise, dosage-form medications, Abbott Laboratories (NYSE:ABT) develops and sells a diverse range of healthcare products including medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. Why Are We Hesitant About ABT? Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 1% over the last two years was below our standards for the healthcare sector Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy 4.7 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position At $133.58 per share, Abbott Laboratories trades at 25.1x forward P/E. If you're considering ABT for your portfolio, see our FREE research report to learn more. One-Month Return: +18.2% Created in 1983 when founder Scott Cook watched his wife struggle to reconcile the family's checkbook, Intuit provides tax and accounting software for small and medium-sized businesses. Why Could INTU Be a Winner? Software platform has product-market fit given the rapid recovery of its customer acquisition costs Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends Intuit's stock price of $772.60 implies a valuation ratio of 10.6x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data